GLP1_NEW
MEDI4166 30 mg injection
MEDI41_SC_30MG_OTHER
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.81 (0.01 to 70.24) | 0.58 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.30 (0.00 to 8.06) | 0.81 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.80 (0.01 to 71.32) | 0.56 |